/PRNewswire/ On January 9, 2024 (Beijing Time), Abbisko Therapeutics (HKEX code: 02256) announced that its investigational innovative CSF-1R inhibitor.
Abbisko Therapeutic announces that EMA has granted orphan drug designation for its CSF-1R inhibitor Pimicotinib ?ABSK021? lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
SHANGHAI, Dec. 4, 2023 /PRNewswire/ On 4 Dec. 2023, Abbisko Therapeutics announced that it has entered into a licensing agreement with Merck, a leading science and technology company.
Abbisko Therapeutics has entered into a licensing agreement with Merck. Under the agreement, Merck will be granted an exclusive license to commercialize products comprising or containing pimicotinib for all indications in Chinese mainland, Hong Kong, Macau and Taiwan, and Abbisko Therapeutics will retain the exclusive rights to develop pimicotinib.